GlobeNewsWire
12 Jul 2026, 13:30 UTC · 2h ago
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
12 Jul 2026, 13:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Evaxion's EVX-V1 preclinical data shows AI-discovered T-cell epitopes can improve control of acute infection, latency, and reactivation in CMV-infected mice. — Positive preclinical progress on a high-unmet-need target (CMV) increases the probability of clinical success, though it is early stage.
+0.40The EVX-V1 program utilizes a multi-component strategy combining novel B-cell antigens, T-cell epitopes, and optimized structural antigens. — A broader targeted approach potentially reduces the risk of vaccine failure compared to single-antigen candidates.
+0.20There are currently no licensed vaccines available for cytomegalovirus (CMV). — Confirms a significant market gap and high commercial potential if the product reaches approval.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company presented positive preclinical data for its CMV vaccine program, marking an important step forward in its development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
